SUMMIT THERAPEUTICS INC logo

SMMT

SUMMIT THERAPEUTICS INC

$0.78

Earnings Summary

Revenue
$24.91Mn
Net Profits
$14.35Mn
Net Profit Margins
57.62%

Highlights

Revenue:

SUMMIT THERAPEUTICS INC’s revenue jumped 248993.11% since last year same period to $24.91Mn in the Q3 2017. On a quarterly growth basis, SUMMIT THERAPEUTICS INC has generated 1014.82% jump in its revenue since last 3-months.

Net Profits:

SUMMIT THERAPEUTICS INC’s net profit jumped 274.85% since last year same period to $14.35Mn in the Q3 2017. On a quarterly growth basis, SUMMIT THERAPEUTICS INC has generated 333.16% jump in its net profits since last 3-months.

Net Profit Margins:

SUMMIT THERAPEUTICS INC’s net profit margin jumped 100.07% since last year same period to 57.62% in the Q3 2017. On a quarterly growth basis, SUMMIT THERAPEUTICS INC has generated 120.91% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the SUMMIT THERAPEUTICS INC post its latest quarter earnings

EPS Estimate Current Quarter
-0.26
EPS Estimate Current Year
-0.26

Highlights

EPS Estimate Current Quarter:

SUMMIT THERAPEUTICS INC’s earning per share (EPS) estimates for the current quarter stand at -0.26 - a 0% jump from last quarter’s estimates.

EPS Estimate Current Year:

SUMMIT THERAPEUTICS INC’s earning per share (EPS) estimates for the current year stand at -0.26.

Key Ratios

Key ratios of the SUMMIT THERAPEUTICS INC post its Q3 2022 earnings

Earning Per Share (EPS)
-0.17
Return on Assets (ROA)
-0.34
Return on Equity (ROE)
-0.74

Highlights

Earning Per Share (EPS):

SUMMIT THERAPEUTICS INC’s earning per share (EPS) jumped 37.04% since last year same period to -0.17 in the Q3 2022. This indicates that the SUMMIT THERAPEUTICS INC has generated 37.04% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. SUMMIT THERAPEUTICS INC’s return on assets (ROA) stands at -0.34.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. SUMMIT THERAPEUTICS INC’s return on equity (ROE) stands at -0.74.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-03-17
-0.27
-0.28
-3.7%
2022-08-11
-0.27
-0.17
37.04%
2022-05-11
-0.28
-0.22
21.43%

Company Information

Summit Therapeutics, empowered by its Discuva Platform, the Company's innovative antibiotic discovery engine, led by Dr. Ventzislav Stefanov and supported by BARDA and Carb-X funding, intends to be the leader in patient and physician friendly paradigm shifting antibiotic innovation. Its new mechanism antibiotics are designed to become the patient-friendly, new era standard-of-care, by working in harmony with the human microbiome to treat prospective patients suffering from infectious disease, initially focussing on Clostridioides difficile infections ("CDI") which is estimated to impact over 3 million patients worldwide annually. Commercialization of ridinilazole for the treatment of CDI is subject to regulatory approvals. The overriding objective of Summit Therapeutics is to create value for patients, hospital infectious disease care givers, community based infectious disease healthcare providers, as well as healthcare payors around the world. Currently, Summit's lead product candidate ridinilazole is engaged in two global phase III trials, Ri-CoDIFy 1 & 2, each enrolling 680 patients vs standard of care (Vancomycin) for the treatment of C. difficile infections.

Organisation
SUMMIT THERAPEUTICS INC
Headquarters
One Broadway, Cambridge, MA, United States, 02142
Employees
105
Industry
Health Technology

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*